查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1535590

外陰陰道念珠菌病 (VVC) 治療市場 - 藥物類別、疾病類型、給藥途徑、類型、配銷通路、全球預測

Vulvovaginal Candidiasis (VVC) Treatment Market - Drug Class, Disease Type, Route of Administration, Type, Distribution Channel, Global Forecast 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於領先製藥公司推出的產品激增，2024 年至 2032 年間，全球外陰陰道念珠菌病 (VVC) 治療市場的複合年成長率將達到 4.5%。 VVC 是一種由念珠菌引起的常見真菌感染，影響全球數百萬名女性，迫切需要有效的治療方法。為此，醫療保健行業的主要參與者正在推出各種創新的抗真菌療法和非處方治療，包括外用乳膏、口服藥物和陰道栓劑。

例如，2024年2月，新興生物製藥公司Mycovia Pharmaceuticals, Inc.宣布江蘇恆瑞製藥有限公司正式在中國上市VIVJOA(R)（奧替康唑）。這種創新的口服唑類抗黴菌藥物現已可用於治療嚴重的外陰陰道念珠菌病 (VVC)。

這些新產品的推出滿足了人們對更有效、更方便、更適合患者的治療方案日益成長的需求。公司正在投資研發以提高療效、降低復發率並最大限度地減少副作用。新型配方和給藥方法的引入體現了滿足不同患者需求和改善治療結果的承諾。隨著市場隨著這些進步而擴大，它有望為 VVC 提供更好的管理解決方案，推動整體市場成長並增強患者護理。

整個外陰陰道念珠菌病（VVC）治療行業根據藥物類別、疾病類型、給藥途徑、類型、配銷通路和地區進行分類。

根據藥物類別，克黴唑領域的外陰陰道念珠菌病(​​VVC) 治療市場收入將在2024 年至2032 年實現值得稱讚的複合年成長率。口服片劑，可有效緩解VVC 症狀是管理這種常見真菌感染的基石。其長期的功效和安全性使其在醫療保健提供者和患者中持續受歡迎。克黴唑的持續供應及其成本效益進一步支持了其市場需求。由於 VVC 仍然普遍存在，克黴唑在治療中的作用確保了其在 VVC 治療領域的持續存在和重要性。

從疾病類型來看，複雜性VVC部分將在2024年至2032年出現顯著成長。這導致人們更加關注開發和行銷創新抗真菌療法，包括更新的口服和局部療法。對有效解決方案的需求是由降低復發率和改善患者治療結果的需求所驅動的。隨著醫療保健提供者尋求更有效的複雜 VVC 管理方案，隨著先進治療解決方案的引入，市場正在擴大。

歐洲外陰陰道念珠菌病(​​VVC) 治療市場將於2024 年至2032 年呈現顯著的複合年成長率。 VVC 是一種影響許多女性的常見真菌感染。該市場是由非處方藥和處方藥（包括外用和口服抗真菌藥物）的需求所推動的。歐洲法規和醫療保健政策進一步支持創新療法的可用性。因此，製藥公司正在積極開發和推出新產品，以滿足該地區對有效 VVC 治療的需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 外陰陰道念珠菌病患病率增加
      • 非處方藥的可用性
      • 越來越關注女性健康
    • 產業陷阱與挑戰
      • 與抗真菌藥物相關的不良反應
  • 成長潛力分析
  • 監管環境
    • 美國
    • 歐洲
    • 亞太地區
  • 管道分析
  • 報銷版圖
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

  • 主要趨勢
  • 氟康唑
  • 克黴唑
  • 咪康唑
  • 制黴菌素
  • 酮康唑
  • 特比萘芬
  • 特康唑
  • 其他藥物類別

第 6 章：市場估計與預測：按疾病類型，2021 - 2032

  • 主要趨勢
  • 簡單的 VVC
  • 複雜的VVC

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 口服
  • 專題
  • 靜脈

第 8 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 處方藥
  • 非處方藥

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Grupo Ferrer Internacional S.A.
  • Johnson & Johnson
  • Mycovia Pharmaceuticals, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Scynexis, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
簡介目錄
Product Code: 9746

Global Vulvovaginal Candidiasis (VVC) Treatment Market will witness 4.5% CAGR between 2024 and 2032 due to the surge in product launches from leading pharmaceutical companies. VVC, a common fungal infection caused by Candida species, affects millions of women globally, prompting a significant need for effective treatments. In response, major players in the healthcare sector are introducing a variety of innovative antifungal therapies and over-the-counter treatments, including topical creams, oral medications, and intravaginal suppositories.

For instance, in February 2024, Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd officially launched VIVJOA(R) (oteseconazole) in China. This innovative oral azole antifungal is now available for treating severe vulvovaginal candidiasis (VVC).

These new product launches address the growing demand for more effective, accessible, and patient-friendly treatment options. Companies are investing in research and development to enhance efficacy, reduce recurrence rates, and minimize side effects. The introduction of novel formulations and delivery methods reflects a commitment to meeting diverse patient needs and improving treatment outcomes. As the market expands with these advancements, it is poised to provide better management solutions for VVC, driving overall market growth and enhancing patient care.

The overall Vulvovaginal Candidiasis (VVC) Treatment Industry is classified based on the drug class, disease type, route of administration, type, distribution channel, and region.

Based on drug class, the vulvovaginal candidiasis (VVC) treatment market revenue from the clotrimazole segment will register a commendable CAGR from 2024 to 2032. Clotrimazole, available in various forms such as creams, suppositories, and oral tablets, offers effective relief from VVC symptoms and is a cornerstone in managing this common fungal infection. Its long-standing efficacy and safety profile contribute to its continued popularity among healthcare providers and patients. The consistent availability of clotrimazole and its cost-effectiveness further support its demand in the market. As VVC remains prevalent, clotrimazole's role in treatment ensures its sustained presence and significance in the VVC treatment landscape.

In terms of disease type, the complicated VVC segment will witness appreciable growth from 2024 to 2032. Complicated VVC, characterized by recurrent or severe infections, often requires more advanced treatment approaches compared to uncomplicated cases. This has led to an increased focus on developing and marketing innovative antifungal treatments, including newer oral and topical therapies. The demand for effective solutions is driven by the need for reduced recurrence rates and improved patient outcomes. As healthcare providers seek more effective management options for complicated VVC, the market is expanding with the introduction of advanced therapeutic solutions.

Europe vulvovaginal candidiasis (VVC) treatment market will exhibit a notable CAGR from 2024 to 2032. With a growing emphasis on women's health, European healthcare systems are prioritizing effective management options for VVC, which is a prevalent fungal infection affecting many women. The market is driven by the need for both over-the-counter and prescription treatments, including topical and oral antifungals. European regulations and healthcare policies further support the availability of innovative therapies. As a result, pharmaceutical companies are actively developing and launching new products to meet the demand for effective VVC treatments across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of vulvovaginal candidiasis
      • 3.2.1.2 Availability of over-the-counter medications
      • 3.2.1.3 Increasing focus on women's health
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with antifungal medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Pipeline analysis
  • 3.6 Reimbursement landscape
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Fluconazole
  • 5.3 Clotrimazole
  • 5.4 Miconazole
  • 5.5 Nystatin
  • 5.6 Ketoconazole
  • 5.7 Terbinafine
  • 5.8 Terconazole
  • 5.9 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Uncomplicated VVC
  • 6.3 Complicated VVC

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Topical
  • 7.4 Intravenous

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription drugs
  • 8.3 OTC drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Accord Healthcare Ltd.
  • 11.2 Amneal Pharmaceuticals LLC
  • 11.3 Astellas Pharma Inc.
  • 11.4 Basilea Pharmaceutica Ltd.
  • 11.5 Bayer AG
  • 11.6 Bristol-Myers Squibb Company
  • 11.7 Grupo Ferrer Internacional S.A.
  • 11.8 Johnson & Johnson
  • 11.9 Mycovia Pharmaceuticals, Inc.
  • 11.10 Mylan N.V.
  • 11.11 Pfizer, Inc.
  • 11.12 Scynexis, Inc.
  • 11.13 Teva Pharmaceutical Industries Ltd.
  • 11.14 Zydus Cadila